ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Activation of the ICOS/ICOS-Ligand Pathway in Antibody-Mediated Kidney Graft Rejection

V. Cantaluppi1, G. Merlotti1, M. Quaglia1, G. Rosso1, N. Clemente1, G. Cappellano1, A. Chiocchetti1, G. Castellano2, U. Dianzani1, G. Camussi3

1Nephrology and Kidney Transplantation Unit, University of Piemonte Orientale (UPO), Novara, Italy, 2Nephrology, Dialysis and Kidney Transplantation Unit, University of Foggia, Foggia, Italy, 3Department of Medical Sciences, University of Torino, Torino, Italy

Meeting: 2020 American Transplant Congress

Abstract number: 244

Keywords: Antibodies, Co-stimulation, Endothelial activation, Kidney transplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Kidney Chronic Antibody Mediated Rejection

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:27pm-3:39pm

Location: Virtual

Related Abstracts
  • Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
  • Monitoring Circulating T Follicular Helper Cells Polarization, Activation and Function Distinguishes Asymptomatic Donor-Specific Anti-HLA Antibody Positive Kidney Transplant Recipients from Those Undergoing Antibody-Mediated Rejection

*Purpose: The costimulatory pathway ICOS/ICOS-Ligand may represent a new therapeutic target in antibody-mediated rejection (ABMR), the major cause of long term kidney graft failure. The aim of this study is to evaluate the role of ICOS/ICOS-Ligand activation in a monocentric cohort of biopsy-proven ABMR in the period 2013-2018.

*Methods: We first performed an epidemiological analysis evaluating ABMR incidence and patient/graft survival at 1, 3 and 5 years, identifying predictors for ABMR with univariate and multivariate Cox regression. We then analyzed plasma levels of ICOS and ICOS-Ligand (ELISA) and their histological expression by immunohistochemistry, comparing ABMR patients with a sex- and age-matched cohort with stable renal function (protocol biopsies). Plasma Extracellular Vesicles (EV) were analyzed by NanoSight technology and FACS/RT-PCR for their protein and RNA content, respectively.

*Results: 367 patients were enrolled (median observation 44 months, IQR 23-64 months): rejection incidence was 13.6% at 1 year and significantly higher in patients with second transplantation (20% vs 9% first , p = 0.034). Graft survival of rejection patients was significantly lower than the control group (p=0.03). Cox multivariate analysis showed that duration of DGF strongly correlated with disease-free survival, which is reduced by 6% for every day of DGF (HR 1,06; p = 0,004). Plasma ICOS levels were significantly higher in ABMR vs. control groups (p<0.05). No difference was observed for ICOS-L plasma levels. By contrast, ICOS-L expression was up-regulated in ABMR patients both at glomerular (p<0,0001) and tubular (p=0,02) level. Staining for ICOS-L was observed in tubular epithelial cells and in endothelial cells in the glomeruli and in peritubular capillaries. Of interest, we also observed intraglomerular staining with ICOS in infiltrating cells characterized by immunohistochemistry as NK cells. Moreover, by Nanosight analysis we observed a significant increase of circulating EV in the ABMR group. EV express on their surface different costimulatory molecules including ICOS, ICOS-L, CD40, CD40L.

*Conclusions: In our monocentric analysis we observed graft and patient survivals in short and medium term similar to those observed in most European centers (respectively 94,3-99,3% at 1 year; 87,3-92,7% at 5 years). Biopsy-proven rejection and DGF were independent determinant of graft loss. ICOS/ICOS-L pathway seems to be a potential therapeutic target in ABMR: the evaluation of soluble ICOS levels, ICOS-carrying circulating EV and ICOS-L expression in biopsies are promising biomarkers of ABMR activity.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cantaluppi V, Merlotti G, Quaglia M, Rosso G, Clemente N, Cappellano G, Chiocchetti A, Castellano G, Dianzani U, Camussi G. Activation of the ICOS/ICOS-Ligand Pathway in Antibody-Mediated Kidney Graft Rejection [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/activation-of-the-icos-icos-ligand-pathway-in-antibody-mediated-kidney-graft-rejection/. Accessed March 8, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.